Danaher Corporation $DHR Position Increased by Aberdeen Group plc

Aberdeen Group plc raised its holdings in shares of Danaher Corporation (NYSE:DHR) by 4.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,158,897 shares of the conglomerate’s stock after purchasing an additional 52,124 shares during the period. Aberdeen Group plc owned about 0.16% of Danaher worth $229,334,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after purchasing an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after acquiring an additional 612,154 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock valued at $1,800,614,000 after acquiring an additional 194,466 shares during the period. Invesco Ltd. boosted its holdings in shares of Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after acquiring an additional 1,450,703 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Danaher by 4.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after acquiring an additional 163,332 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

DHR stock opened at $202.53 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The company has a 50-day simple moving average of $200.66 and a 200 day simple moving average of $197.25. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.41. The company has a market capitalization of $145.02 billion, a P/E ratio of 43.09, a PEG ratio of 2.91 and a beta of 0.77.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. During the same period in the previous year, the business earned $1.72 earnings per share. Danaher’s revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s payout ratio is 27.23%.

Wall Street Analyst Weigh In

DHR has been the subject of several analyst reports. Bank of America reduced their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Guggenheim reissued a “buy” rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Wells Fargo & Company reduced their price target on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a report on Tuesday, September 2nd. Finally, UBS Group reduced their price objective on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $244.60.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.